Legal & General Group
IMDX

Legal & General Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Legal & General Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-292
Closed -$9K – 3615
2022
Q1 		$9K Hold
292
– – ﹤0.01% 3427
2021
Q4 		$13K Hold
292
– – ﹤0.01% 3406
2021
Q3 		$21K Sell
292
-53
-15% -$4.87K ﹤0.01% 3261
2021
Q2 		$40K Sell
345
-49
-12% -$4.78K ﹤0.01% 3023
2021
Q1 		$41K Buy
394
+17
+5% +$1.61K ﹤0.01% 2881
2020
Q4 		$18K Hold
377
– – ﹤0.01% 3138
2020
Q3 		$10K Buy
377
+22
+6% +$631 ﹤0.01% 3236
2020
Q2 		$14K Buy
355
+209
+143% +$10.8K ﹤0.01% 3220
2020
Q1 		$7K Sell
146
-71
-33% -$3.48K ﹤0.01% 3221
2019
Q4 		$9K Buy
217
+38
+21% +$1.37K ﹤0.01% 3307
2019
Q3 		$7K Hold
179
– – ﹤0.01% 3304
2019
Q2 		$9K Buy
+179
New +$14.9K ﹤0.01% 3377
2018
Q2 		– Sell
-19
Closed -$1K – 3373
2018
Q1 		$1K Hold
19
– – ﹤0.01% 3278
2017
Q4 		$2K Sell
19
-87
-82% -$9.81K ﹤0.01% 3278
2017
Q3 		$16K Hold
106
– – ﹤0.01% 3217
2017
Q2 		$11K Buy
+106
New +$12.1K ﹤0.01% 3306

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Legal & General Group's IMDX Position: Q2 2022 in Review

Legal & General Group sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 292 shares — an estimated $9K sold.

Legal & General Group first reported a position in IMDX in Q2 2017 and held it in 16 quarters. The position peaked at $41K in Q1 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • Legal & General Group reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 292 Insight Molecular Diagnostics shares in Q2 2022, an estimated $9K.
  • Legal & General Group first reported a position in Insight Molecular Diagnostics in Q2 2017 and held it in 16 quarters.
  • Legal & General Group's Insight Molecular Diagnostics position peaked at $41K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.